Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Sufentanil for Post-Operative Pain
NCT02356588Phase 3Completed
- Sponsor
- Talphera
- Start
- Feb 2015
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SurBred in postoperative pain (2 arms), sponsored by Talphera. Primary endpoint: Time-weighted Summed Pain Intensity Difference Over the 12-hour Study Period. Started Feb 2015; status: completed.
02
Drugs
SurBred
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02356588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356588.